Severe oral mucositis and healthcare utilization in adults with acute lymphoblastic leukemia receiving myeloablative total body irradiation–based conditioning
PURPOSE: We evaluated the association between total body irradiation (TBI) dose and severe oral mucositis (OM) in adults with acute lymphoblastic leukemia (ALL) undergoing myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: We analyzed 101 adults receiving 8 or 12 Gy TBI. Severe OM was defined as WHO grades 3-4. TBI allocation was non-randomized, with 8 Gy more frequently used in older patients and those with a Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) > 3. Multivariable logistic regression assessed factors associated with severe OM, with the Karnofsky Performance Status (KPS) included in the primary model; sensitivity analyses evaluated alternative models. RESULTS: Severe OM occurred in 48 patients (47.5%) and was more frequent after 12 than 8 Gy (62.0% vs. 33.3%, P = 0.005). In the primary model, 12 Gy TBI was associated with higher odds of severe OM (OR 2.78, 95% CI 1.17-6.78; P = 0.022). The association between 12 Gy TBI and severe OM remained significant when HCT-CI replaced KPS and after calendar-year adjustment. After age adjustment, the estimate was similar, but the confidence interval widened and included the null (OR 2.63, 95% CI 0.90-8.06; P = 0.081). Severe OM was associated with a 4-day longer median hospital stay (41 vs. 37 days, P = 0.001) and a 5-day longer median duration of systemic therapeutic antibiotic treatment (20 vs. 15 days, P = 0.002). Neither measure differed significantly by TBI dose. CONCLUSION: Higher TBI dose was associated with severe OM; severe OM was associated with longer hospital stays and systemic therapeutic antibiotic treatment. Findings should be interpreted cautiously given non-randomized TBI allocation. CLINICAL TRIAL REGISTRATION: This study is a retrospective analysis and was not registered as a clinical trial.
Authors
- Isabella Gruber (ORCID: https://orcid.org/0000-0002-7435-9337)
- Ernst Holler (ORCID: https://orcid.org/0000-0003-2295-2187)
- Daniel Wolff (ORCID: https://orcid.org/0000-0001-7015-3190)
- Elisabeth Meedt
- Hendrik Poeck (ORCID: https://orcid.org/0000-0002-0836-2095)
- Daniela Weber (ORCID: https://orcid.org/0000-0003-3833-6311)
- Oliver Koelbl
- Matthias Edinger (ORCID: https://orcid.org/0000-0003-2889-2533)
- Wolfgang Herr (ORCID: https://orcid.org/0009-0001-3991-2256)
Institutions
- University Hospital Regensburg (DE)
- Leibniz Institute for Immunotherapy (DE)
Publication Details
- Journal
- Supportive Care in Cancer
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1007/s00520-026-11471-7
- Primary Topic
- Oral health in cancer treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitätsklinikum Regensburg